Google's services have been blocked in China for several years, but the company still has businesses there, as the tech giant seeks to sell products to Chinese firms in...Technologyread more
Netflix can sustain its lofty valuation only if global subscriber growth can support increasing content spending and debt.Technologyread more
The House voted to table a resolution to start impeachment proceedings against President Donald Trump introduced by Rep. Al Green.Politicsread more
A photo editing app has introduced a few new wrinkles to the faces of celebrities — and to the ongoing discussion around personal digital security, NBC reports.Technologyread more
Stocks in Asia traded lower on Thursday morning. Australia's jobs data showed the net number of jobs created was far below expectations.Asia Marketsread more
Property price gains across the wider U.K. have been slowing since 2016, according to the U.K.'s Office for National Statistics.Real Estateread more
The International Monetary Fund on Wednesday said that the U.S. dollar was overvalued by 6% to 12%, based on near-term economic fundamentals, while the euro, Japan's yen and...World Economyread more
The company blamed its Q2 content slate and price increases for the subscriber miss.Technologyread more
IBM's year-over-year revenue has now declined for four quarters in a row. Impact from Red Hat is not yet factored into the company's guidance.Technologyread more
See which stocks are posting big moves after the bell on July 17.Market Insiderread more
"It's clearly doing more harm than good," the "Mad Money" host says. Instead Facebook should buy Square for $70 billion and expand the payments network worldwide.Mad Money with Jim Cramerread more
Bristol-Myers Squibb shareholders approved the pharmaceutical giant's $74 billion acquisition of cancer drugmaker Celgene in a vote on Friday.
The deal, announced in January, was a hard sell to Bristol shareholders from the start, and the approval concludes a tumultuous period for Bristol, which saw pushback from institutional investors.
The acquisition adds about $32 billion in fresh debt to Bristol's balance sheet while assuming $20 billion in Celgene's debt, the companies said at the time.
More than 70% of eligible shareholders voted for the deal, the company said Friday. Roughly 24% of shareholders voted against the deal, and 1% abstained. Both Bristol and Celgene shares were slightly higher in morning trading.
"We are pleased with the outcome of today's Special Meeting and thank our shareholders for their support for this combination," Bristol's Chairman and CEO Giovanni Caforio said in a statement.
Buying Celgene was seen by Wall Street analysts as giving Bristol more cancer drugs at a time when its immuno-oncology portfolio struggles to keep up with rival Merck's. Bristol's blockbuster Opdivo, which boosts the immune system to attack cancer, has fallen behind its leading competitor, Merck's Keytruda.
Hedge funds Wellington Management and Starboard Value in late February said the deal didn't sit well with them. Wellington — which is Bristol's largest institutional holder — said the deal asked Bristol shareholders to accept too much risk. Starboard cited similar concerns, saying the Celgene deal was "poorly conceived and ill-advised."
Starboard eventually ended its fight against the buyout once Institutional Shareholder Services and Glass Lewis recommended Bristol-Myers shareholders vote in favor of its bid.
For more on investing in health-care innovation, click here to join CNBC at our Healthy Returns Summit in New York City on May 21.
Bristol said Friday the deal, which is expected to close in the third quarter of this year, will create a "premier innovative biopharma company with leading scientific capabilities."
"We look forward to bringing the companies together, which we believe will deliver significant shareholder value," Caforio said.